AR103711A2 - Procedimiento para modificar formación de cristal de fármaco, cristales modificados y composiciones que los contienen - Google Patents
Procedimiento para modificar formación de cristal de fármaco, cristales modificados y composiciones que los contienenInfo
- Publication number
- AR103711A2 AR103711A2 ARP160100409A ARP160100409A AR103711A2 AR 103711 A2 AR103711 A2 AR 103711A2 AR P160100409 A ARP160100409 A AR P160100409A AR P160100409 A ARP160100409 A AR P160100409A AR 103711 A2 AR103711 A2 AR 103711A2
- Authority
- AR
- Argentina
- Prior art keywords
- drug substance
- crystals
- crystal habit
- procedure
- acicular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Furan Compounds (AREA)
Abstract
Se describe un procedimiento para modificar el hábito de cristal de sustancias de fármaco aciculares, cristales obtenidos a través de dicho procedimiento, y formas de cristal particulares o modificaciones de ácido micofenólico o micofenolato de sodio, así como composiciones farmacéuticas que comprenden los cristales, métodos y tratamiento y usos de los mismos. Reivindicación 1: Un procedimiento para modificar el hábito de cristal de una sustancia de fármaco acicular, caracterizada porque la sustancia de fármaco acicular es una sal de sodio de micofenolato, que comprende suspender dicha sustancia de fármaco cristalina en un sistema de solvente metanol / agua en una relación en el rango entre 98:2 y 90:10 y, y someter dicha suspensión a una oscilación de temperatura, donde el hábito de cristal es modificado y que la relación de aspecto media de los cristales procesados es menor que 10:1 y la densidad aparente es mayor que 200 kg/m³. Reivindicación 2: Un procedimiento para recristalizar una sustancia de fármaco acidular cristalina caracterizada porque la sustancia de fármaco acicular es una sal de sodio de micofenolato, que comprende suspender dicha sustancia de fármaco cristalina en un sistema de solvente metanol / agua en una relación en el rango entre 98:2 y 90:10 y, y someter dicha suspensión a una oscilación de temperatura, donde el hábito de cristal es modificado ya que la relación de aspecto media de los cristales procesados es menor que 10:1 y la densidad aparente es mayor que 200 kg/m³.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0301259.8A GB0301259D0 (en) | 2003-01-20 | 2003-01-20 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103711A2 true AR103711A2 (es) | 2017-05-31 |
Family
ID=9951448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100142A AR043343A1 (es) | 2003-01-20 | 2004-01-19 | Procedimiento para modificar formacion de cristal de farmaco |
| ARP160100409A AR103711A2 (es) | 2003-01-20 | 2016-02-15 | Procedimiento para modificar formación de cristal de fármaco, cristales modificados y composiciones que los contienen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100142A AR043343A1 (es) | 2003-01-20 | 2004-01-19 | Procedimiento para modificar formacion de cristal de farmaco |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20060122265A1 (es) |
| EP (2) | EP1592401B1 (es) |
| JP (1) | JP4549976B2 (es) |
| KR (5) | KR20090115821A (es) |
| CN (2) | CN100595199C (es) |
| AR (2) | AR043343A1 (es) |
| AT (1) | ATE546132T1 (es) |
| AU (1) | AU2004206731B2 (es) |
| BR (1) | BRPI0406827A (es) |
| CA (2) | CA2509796C (es) |
| CL (1) | CL2004000073A1 (es) |
| CO (1) | CO5580738A2 (es) |
| CY (1) | CY1112772T1 (es) |
| DK (1) | DK1592401T3 (es) |
| EC (1) | ECSP055918A (es) |
| ES (1) | ES2382035T3 (es) |
| GB (1) | GB0301259D0 (es) |
| HK (1) | HK1084874A1 (es) |
| IL (1) | IL169484A (es) |
| MX (1) | MXPA05007691A (es) |
| MY (1) | MY148297A (es) |
| NO (1) | NO20053846L (es) |
| NZ (1) | NZ541073A (es) |
| PE (2) | PE20110276A1 (es) |
| PL (2) | PL213192B1 (es) |
| PT (1) | PT1592401E (es) |
| RU (1) | RU2388757C2 (es) |
| SG (1) | SG155046A1 (es) |
| SI (1) | SI1592401T1 (es) |
| TW (1) | TWI325785B (es) |
| WO (1) | WO2004064806A2 (es) |
| ZA (1) | ZA200504442B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124953D0 (en) | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| GB0301259D0 (en) | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
| AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| CA2553881A1 (en) | 2004-04-26 | 2005-11-10 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Process for preparation of mycophenolic acid and ester derivatives thereof |
| EP1740563A2 (en) | 2004-04-27 | 2007-01-10 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Mycophenolate mofetil impurity |
| EP1699773A2 (en) | 2004-07-20 | 2006-09-13 | Ceva Gyogyszergyar R Szv Nytarsasag | Processes for preparation of crystalline mycophenolate sodium |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| US20080176937A1 (en) * | 2007-01-23 | 2008-07-24 | Apotex Fermentation Inc. | Novel crystalline mycophenolate sodium polymorph and processes to manufacture same |
| PT2349220E (pt) * | 2008-10-09 | 2012-10-11 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Utilização de solventes orgânicos na granulação húmida de moxifloxacina |
| CN101756958B (zh) * | 2008-11-10 | 2011-07-20 | 鲁南制药集团股份有限公司 | 一种治疗关节炎的药物组合物及其制备方法 |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| PL2451797T3 (pl) | 2009-07-10 | 2013-08-30 | Janssen Pharmaceutica Nv | Proces krystalizacji dla 1-(ß-D-glukopiranozylo)-4-metylo-3-[5-(4-fluorofenylo)-2-tienylometylo]benzenu |
| EP2488173A1 (en) * | 2009-10-13 | 2012-08-22 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
| CN103221391B (zh) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法 |
| BR112012028857B1 (pt) | 2010-05-11 | 2021-02-09 | Janssen Pharmaceutica Nv | Composições farmacêuticas administráveis por via oral que compreendem derivados de 1- (beta-d glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt |
| CN103880799A (zh) * | 2010-11-16 | 2014-06-25 | 北京京卫信康医药科技发展有限公司 | 麦考酚酸钠的新晶型及其制备方法 |
| CN103880800A (zh) * | 2010-11-16 | 2014-06-25 | 北京京卫信康医药科技发展有限公司 | 麦考酚酸钠的新晶型及其制备方法 |
| CN103596944B (zh) | 2011-04-13 | 2017-02-22 | 詹森药业有限公司 | 可用作sglt2的抑制剂的化合物的制备方法 |
| TWI582078B (zh) * | 2013-01-23 | 2017-05-11 | 北京貝美拓新藥研發有限公司 | 抑制脯氨酸羥化酶活性的化合物的晶型及其應用 |
| US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| WO2017108752A1 (en) * | 2015-12-21 | 2017-06-29 | Janssen Pharmaceutica Nv | Crystallization procedure for obtaining canagliflozin hemihydrate crystals |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
| CN108727318A (zh) * | 2017-04-25 | 2018-11-02 | 鲁南制药集团股份有限公司 | 麦考酚酸的晶型物 |
| CN108727317A (zh) * | 2017-04-25 | 2018-11-02 | 鲁南制药集团股份有限公司 | 一种麦考酚酸的晶型物 |
| CN110922371B (zh) * | 2019-12-27 | 2020-08-11 | 广东蓝宝制药有限公司 | 一种m2晶型麦考酚钠的制备方法 |
| WO2023234158A1 (ja) * | 2022-05-31 | 2023-12-07 | 本州化学工業株式会社 | ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US158835A (en) * | 1875-01-19 | Improvement in mortising-tools | ||
| GB935432A (en) * | 1958-05-29 | 1963-08-28 | Secr Aviation | Improvements in the manufacture of crystalline substances |
| US3187039A (en) * | 1962-10-19 | 1965-06-01 | Commercial Solvents Corp | Method for changing the crystal habit of monosodium glutamate |
| US3183263A (en) * | 1962-10-19 | 1965-05-11 | Commercial Solvents Corp | Method for changing the crystal habit of mono-sodium glutamate |
| US3352906A (en) * | 1963-02-04 | 1967-11-14 | Charles R Parkerson | Habit modification and preparation of single crystal triglycine sulfate |
| US3770390A (en) * | 1971-02-26 | 1973-11-06 | Dow Chemical Co | Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates |
| US4259239A (en) * | 1980-04-21 | 1981-03-31 | Allied Chemical Corporation | Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam |
| IL60254A (en) | 1980-06-08 | 1983-11-30 | Yeda Res & Dev | Resolution of amino acids |
| JPS5875194A (ja) * | 1981-10-30 | 1983-05-06 | 株式会社日立製作所 | マトリクス表示装置及び駆動方法 |
| JPS59232916A (ja) * | 1983-06-16 | 1984-12-27 | Shiraishi Chuo Kenkyusho:Kk | 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物 |
| IL77031A (en) | 1985-11-12 | 1995-12-08 | Yeda Res & Dev | Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors |
| JPH0745359B2 (ja) | 1987-12-25 | 1995-05-17 | 東レ株式会社 | 有機化合物結晶の製造方法 |
| EP0582452B1 (en) * | 1992-08-04 | 1998-10-14 | Toda Kogyo Corp. | Granulated particles for magnetic particles for magnetic recording and process for producing the same |
| ATE173475T1 (de) | 1993-09-15 | 1998-12-15 | Syntex Inc | Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung |
| JPH09209297A (ja) * | 1996-01-26 | 1997-08-12 | Nippon Paper Ind Co Ltd | 艶消し軽量塗工紙及びその製造方法 |
| ID18663A (id) | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| KR100491274B1 (ko) * | 1996-04-12 | 2005-09-05 | 노파르티스 아게 | 미코페놀레이트의장용코팅된약제조성물 |
| FR2780403B3 (fr) * | 1998-06-24 | 2000-07-21 | Sanofi Sa | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
| GB0301259D0 (en) * | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
-
2003
- 2003-01-20 GB GBGB0301259.8A patent/GB0301259D0/en not_active Ceased
-
2004
- 2004-01-19 TW TW093101302A patent/TWI325785B/zh not_active IP Right Cessation
- 2004-01-19 EP EP04703158A patent/EP1592401B1/en not_active Revoked
- 2004-01-19 PL PL393385A patent/PL213192B1/pl unknown
- 2004-01-19 KR KR1020097022060A patent/KR20090115821A/ko active Search and Examination
- 2004-01-19 PT PT04703158T patent/PT1592401E/pt unknown
- 2004-01-19 PE PE2011000069A patent/PE20110276A1/es active IP Right Grant
- 2004-01-19 US US10/541,504 patent/US20060122265A1/en not_active Abandoned
- 2004-01-19 MX MXPA05007691A patent/MXPA05007691A/es active IP Right Grant
- 2004-01-19 SG SG200700660-4A patent/SG155046A1/en unknown
- 2004-01-19 CN CN200480002455A patent/CN100595199C/zh not_active Expired - Lifetime
- 2004-01-19 NZ NZ541073A patent/NZ541073A/en not_active IP Right Cessation
- 2004-01-19 PE PE2004000074A patent/PE20040826A1/es not_active Application Discontinuation
- 2004-01-19 PL PL376525A patent/PL376525A1/pl not_active Application Discontinuation
- 2004-01-19 DK DK04703158.8T patent/DK1592401T3/da active
- 2004-01-19 JP JP2005518641A patent/JP4549976B2/ja not_active Expired - Fee Related
- 2004-01-19 AU AU2004206731A patent/AU2004206731B2/en not_active Expired
- 2004-01-19 AT AT04703158T patent/ATE546132T1/de active
- 2004-01-19 EP EP10177718A patent/EP2308471A1/en not_active Withdrawn
- 2004-01-19 CN CNA2008101443548A patent/CN101333201A/zh active Pending
- 2004-01-19 CA CA2509796A patent/CA2509796C/en not_active Expired - Lifetime
- 2004-01-19 WO PCT/EP2004/000354 patent/WO2004064806A2/en active Application Filing
- 2004-01-19 KR KR1020057013313A patent/KR100855149B1/ko active IP Right Grant
- 2004-01-19 CA CA2706900A patent/CA2706900A1/en not_active Abandoned
- 2004-01-19 MY MYPI20040142A patent/MY148297A/en unknown
- 2004-01-19 RU RU2005126328/04A patent/RU2388757C2/ru active
- 2004-01-19 KR KR1020097022061A patent/KR101129105B1/ko active IP Right Grant
- 2004-01-19 BR BR0406827-0A patent/BRPI0406827A/pt not_active Application Discontinuation
- 2004-01-19 SI SI200431859T patent/SI1592401T1/sl unknown
- 2004-01-19 KR KR1020077016703A patent/KR20070087181A/ko not_active Application Discontinuation
- 2004-01-19 KR KR1020107024515A patent/KR20100120321A/ko not_active Application Discontinuation
- 2004-01-19 AR ARP040100142A patent/AR043343A1/es unknown
- 2004-01-19 ES ES04703158T patent/ES2382035T3/es not_active Expired - Lifetime
- 2004-01-20 CL CL200400073A patent/CL2004000073A1/es unknown
-
2005
- 2005-05-31 ZA ZA200504442A patent/ZA200504442B/en unknown
- 2005-06-30 IL IL169484A patent/IL169484A/en active IP Right Grant
- 2005-07-15 EC EC2005005918A patent/ECSP055918A/es unknown
- 2005-07-25 CO CO05072728A patent/CO5580738A2/es not_active Application Discontinuation
- 2005-08-16 NO NO20053846A patent/NO20053846L/no not_active Application Discontinuation
-
2006
- 2006-04-26 HK HK06104995.1A patent/HK1084874A1/xx not_active IP Right Cessation
-
2008
- 2008-12-18 US US12/337,663 patent/US8008511B2/en not_active Expired - Lifetime
-
2011
- 2011-08-04 US US13/198,022 patent/US8124795B2/en not_active Expired - Lifetime
-
2012
- 2012-05-14 CY CY20121100450T patent/CY1112772T1/el unknown
-
2016
- 2016-02-15 AR ARP160100409A patent/AR103711A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103711A2 (es) | Procedimiento para modificar formación de cristal de fármaco, cristales modificados y composiciones que los contienen | |
| PA8609201A1 (es) | Piridinonas sustituidas | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| BR0116429A (pt) | piridoindóis substituìdos como agonistas e antagonistas da serotonina | |
| CO5560540A2 (es) | Composicion cristalina que contiene escitalopram | |
| CO6260141A2 (es) | Inhibidores del co-transportador 2 sodio glucosa y metodos para la preparacion de los mismos y sus intermediarios | |
| UY24864A1 (es) | Metodo para preparar y purificar un derivado n-alcohilado de aspartamo | |
| PE20081390A1 (es) | Procedimiento para producir derivados de amina opticamente activos | |
| EA200702319A1 (ru) | Фармацевтические лекарственные формы, содержащие липидную фазу | |
| KR870008906A (ko) | 마크로라이드 유도체의 제조방법 | |
| Kaus | The effect of aminoglycoside antibiotics on the lateral line organ of Aplocheilus lineatus (Cyprinodontidae) | |
| PT86121B (pt) | Processo para a preparacao de sal de acido 2-{(2,6-diclorofenil)-amino}-benzeno-acetico com uma base organica ciclica e de composicoes farmaceuticas contendo o mesmo | |
| JP6597166B2 (ja) | 動物細胞の再生速度制御方法及び再生速度制御装置 | |
| ES2369888T3 (es) | Derivados de adamantano novedosos con actividades neuroprotectoras, antidepresivas y antiisquémicas, y procedimiento para preparar los mismos. | |
| DE2235935A1 (de) | Neue derivate von trijodierten aminobenzolcarbonsaeuren, ein verfahren zu deren herstellung und deren verwendung | |
| KR970706844A (ko) | 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor) | |
| ES2267421T1 (es) | Procedimiento para la preparacion de acido (6rs)-n(5)-formil-5,6,7,8-tetrahidrofolico cristalino. | |
| Zhang et al. | Inhibition of Crystal Nucleation and Growth: A Review | |
| AR029436A1 (es) | Compuestos de eteres de dicarboxilato de calcio, metodos para su preparacion y su uso en tratamiento de las enfermedades vasculares y diabetes, composicion farmaceutica, formas cristalinas. | |
| Anderson et al. | Oral Toxicity of Certain Alkyl Resorcinols in Guinea Pigs and Rabbits. | |
| AR045681A1 (es) | Proceso para la sintesis de intermediarios de inhibidores de betalactamasa | |
| Court et al. | Study on the activity of antiparasitic agents against Onchocerca lienalis third stage larvae in vitro | |
| Bastos | Étude de la contamination de l'environnement par les médicaments à usage humain et vétérinaire dans le sud du Brésil | |
| ES2076326T3 (es) | Purificador para agua de refrigeracion de reactor nuclear y metodo de purificacion. | |
| Ariani et al. | Experimentally induced mineral phase change and morphological aberrations in CaCO3 statoliths of Mysidacea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |